Format
Sort by
Items per page

Send to

Choose Destination

Best matches for O’Byrne PM[au]:

The paradoxes of asthma management: time for a new approach? O'Byrne PM et al. Eur Respir J. (2017)

Asthma and exercise-induced bronchoconstriction in athletes. Boulet LP et al. N Engl J Med. (2015)

A summary of the new GINA strategy: a roadmap to asthma control. Reddel HK et al. Eur Respir J. (2015)

Search results

Items: 1 to 50 of 431

1.

Cholinergic synapse pathway gene polymorphisms associated with allergen-induced late asthmatic responses.

Rajasekaran A, He D, Yue A, Singh A, Shannon CP, FitzGerald JM, Boulet LP, O'Byrne PM, Gauvreau GM, Tebbutt SJ.

ERJ Open Res. 2019 Nov 4;5(4). pii: 00107-2019. doi: 10.1183/23120541.00107-2019. eCollection 2019 Oct.

2.

The presence of Aspergillus fumigatus in asthmatic airways is not clearly related to clinical disease severity.

Sullivan A, Hunt EB, Ward C, Lapthorne S, Eustace JA, Fanning LJ, Plant BJ, O'Byrne PM, MacSharry JA, Murphy DM.

Allergy. 2019 Oct 12. doi: 10.1111/all.14087. [Epub ahead of print]

PMID:
31605638
3.

The Global Initiative for Asthma (GINA): 25 years later.

Boulet LP, Reddel HK, Bateman E, Pedersen S, FitzGerald JM, O'Byrne PM.

Eur Respir J. 2019 Aug 29;54(2). pii: 1900598. doi: 10.1183/13993003.00598-2019. Print 2019 Aug. Review.

PMID:
31273040
4.

Effects of interleukin-6 receptor blockade on allergen-induced airway responses in mild asthmatics.

Revez JA, Bain LM, Watson RM, Towers M, Collins T, Killian KJ, O'Byrne PM, Gauvreau GM, Upham JW, Ferreira MA.

Clin Transl Immunology. 2019 Jun 14;8(6):e1044. doi: 10.1002/cti2.1044. eCollection 2019.

5.

Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study.

Duong M, Islam S, Rangarajan S, Leong D, Kurmi O, Teo K, Killian K, Dagenais G, Lear S, Wielgosz A, Nair S, Mohan V, Mony P, Gupta R, Kumar R, Rahman O, Yusoff K, du Plessis JL, Igumbor EU, Chifamba J, Li W, Lu Y, Zhi F, Yan R, Iqbal R, Ismail N, Zatonska K, Karsidag K, Rosengren A, Bahonar A, Yusufali A, Lamelas PM, Avezum A, Lopez-Jaramillo P, Lanas F, O'Byrne PM, Yusuf S; PURE investigators.

Lancet Glob Health. 2019 May;7(5):e613-e623. doi: 10.1016/S2214-109X(19)30070-1.

6.

Fluticasone furoate/vilanterol versus fluticasone propionate in patients with asthma and exercise-induced bronchoconstriction.

Martin N, Weiler JM, Pearlman D, Jacques L, Nunn C, Forth R, West S, Dunn K, O'Byrne PM.

J Asthma. 2019 Feb 22:1-10. doi: 10.1080/02770903.2019.1579344. [Epub ahead of print]

PMID:
30795705
7.

The interleukin-13 paradox in asthma: effective biology, ineffective biologicals.

Nair P, O'Byrne PM.

Eur Respir J. 2019 Jan 31;53(2). pii: 1802250. doi: 10.1183/13993003.02250-2018. Print 2019 Feb. No abstract available.

PMID:
30760544
8.

Effect of sex on group 2 innate lymphoid cells in the airways of mild and severe asthmatics.

Aw M, Nair P, Salter B, Chen R, Machida K, Inman M, O'Byrne PM, Gauvreau GM, Sehmi R.

Allergy. 2019 Jul;74(7):1397-1400. doi: 10.1111/all.13742. Epub 2019 Feb 26. No abstract available.

PMID:
30741429
9.

Allergen challenge increases capsaicin-evoked cough responses in patients with allergic asthma.

Satia I, Watson R, Scime T, Dockry RJ, Sen S, Ford JW, Mitchell PD, Fowler SJ, Gauvreau GM, O'Byrne PM, Smith JA.

J Allergy Clin Immunol. 2019 Sep;144(3):788-795.e1. doi: 10.1016/j.jaci.2018.11.050. Epub 2019 Jan 17.

PMID:
30660644
10.

Advances in the treatment of mild asthma: recent evidence.

O'Byrne PM, Mejza F.

Pol Arch Intern Med. 2018 Sep 28;128(9):545-549. doi: 10.20452/pamw.4341. Epub 2018 Sep 28. Review.

11.

Combined Analysis of Asthma Safety Trials of Long-Acting β2-Agonists.

Busse WW, Bateman ED, Caplan AL, Kelly HW, O'Byrne PM, Rabe KF, Chinchilli VM.

N Engl J Med. 2018 Jun 28;378(26):2497-2505. doi: 10.1056/NEJMoa1716868.

12.

Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.

O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK.

N Engl J Med. 2018 May 17;378(20):1865-1876. doi: 10.1056/NEJMoa1715274.

13.

As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma.

Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM.

N Engl J Med. 2018 May 17;378(20):1877-1887. doi: 10.1056/NEJMoa1715275.

14.

Expression of IL-33 and TSLP and Their Receptors in Asthmatic Airways after Inhaled Allergen Challenge.

Al-Sajee D, Sehmi R, Hawke TJ, El-Gammal A, Howie KJ, Watson RM, Londei M, Gauvreau GM, O'Byrne PM.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):805-807. doi: 10.1164/rccm.201712-2468LE. No abstract available.

PMID:
29733677
15.

Two pathways, one patient; UK asthma guidelines.

Fowler SJ, O'Byrne PM, Buhl R, Shaw D.

Thorax. 2018 Sep;73(9):797-798. doi: 10.1136/thoraxjnl-2018-211703. Epub 2018 May 3. No abstract available.

PMID:
29724867
16.

Giants in Chest Medicine: Professor Emeritus Elizabeth F. Juniper, MCSP, MSc.

O'Byrne PM.

Chest. 2018 Apr;153(4):776-777. doi: 10.1016/j.chest.2018.01.017. No abstract available.

PMID:
29626968
17.

Interleukin-25 and eosinophils progenitor cell mobilization in allergic asthma.

Tang W, Smith SG, Du W, Gugilla A, Du J, Oliveria JP, Howie K, Salter BM, Gauvreau GM, O'Byrne PM, Sehmi R.

Clin Transl Allergy. 2018 Feb 13;8:5. doi: 10.1186/s13601-018-0190-2. eCollection 2018.

18.

Evolving Concepts in Asthma.

O'Byrne PM.

Semin Respir Crit Care Med. 2018 Feb;39(1):1-2. doi: 10.1055/s-0037-1620250. Epub 2018 Feb 10. No abstract available.

PMID:
29427979
19.

The effects of a CCR3 inhibitor, AXP1275, on allergen-induced airway responses in adults with mild-to-moderate atopic asthma.

Gauvreau GM, FitzGerald JM, Boulet LP, Watson RM, Hui L, Villineuve H, Scime TX, Schlatman AR, Obminski C, Kum J, Boehme S, Ly TW, Bacon KB, O'Byrne PM.

Clin Exp Allergy. 2018 Apr;48(4):445-451. doi: 10.1111/cea.13114. Epub 2018 Mar 13.

PMID:
29423947
20.

Sputum cytology during late-phase responses to inhalation challenge with different allergens.

Revez JA, Killian KJ, O'Byrne PM, Boulet LP, Upham JW, Gauvreau GM, Ferreira MAR.

Allergy. 2018 Jul;73(7):1470-1478. doi: 10.1111/all.13415. Epub 2018 Feb 6.

PMID:
29337345
21.

Changes in regulatory B-cell levels in bone marrow, blood, and sputum of patients with asthma following inhaled allergen challenge.

Oliveria JP, El-Gammal AI, Yee M, Obminski CD, Scime TX, Watson RM, Howie K, O'Byrne PM, Sehmi R, Gauvreau GM.

J Allergy Clin Immunol. 2018 Apr;141(4):1495-1498.e9. doi: 10.1016/j.jaci.2017.11.013. Epub 2017 Dec 6. No abstract available.

22.

Novel Blood-based Transcriptional Biomarker Panels Predict the Late-Phase Asthmatic Response.

Singh A, Shannon CP, Kim YW, Yang CX, Balshaw R, Cohen Freue GV, Gauvreau GM, FitzGerald JM, Boulet LP, O'Byrne PM, Tebbutt SJ.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):450-462. doi: 10.1164/rccm.201701-0110OC.

PMID:
29087730
23.

The paradoxes of asthma management: time for a new approach?

O'Byrne PM, Jenkins C, Bateman ED.

Eur Respir J. 2017 Sep 9;50(3). pii: 1701103. doi: 10.1183/13993003.01103-2017. Print 2017 Sep. Review.

24.

Methacholine Challenge: Comparison of Airway Responsiveness Produced by a Vibrating Mesh Nebulizer Versus a Jet Nebulizer.

Blais CM, Cockcroft DW, Veilleux J, Boulay MÈ, Boulet LP, Gauvreau GM, Scime TX, Watson RM, O'Byrne PM, Davis BE.

J Aerosol Med Pulm Drug Deliv. 2018 Apr;31(2):88-93. doi: 10.1089/jamp.2017.1392. Epub 2017 Aug 16.

PMID:
28813613
25.

Targeting Eosinophils in Eosinophilic Granulomatosis with Polyangiitis.

Djukanovic R, O'Byrne PM.

N Engl J Med. 2017 May 18;376(20):1985-1986. doi: 10.1056/NEJMe1704402. No abstract available.

PMID:
28514619
26.

Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment.

Jenkins CR, Eriksson G, Bateman ED, Reddel HK, Sears MR, Lindberg M, O'Byrne PM.

BMC Pulm Med. 2017 Apr 20;17(1):65. doi: 10.1186/s12890-017-0401-y.

27.

Allergen-induced Increases in Sputum Levels of Group 2 Innate Lymphoid Cells in Subjects with Asthma.

Chen R, Smith SG, Salter B, El-Gammal A, Oliveria JP, Obminski C, Watson R, O'Byrne PM, Gauvreau GM, Sehmi R.

Am J Respir Crit Care Med. 2017 Sep 15;196(6):700-712. doi: 10.1164/rccm.201612-2427OC.

PMID:
28422515
28.

The Potential Role of Aspiration in the Asthmatic Airway.

Hunt EB, Ward C, Power S, Sullivan A, Pearson JP, Lapthorne S, O'Byrne PM, Eustace J, Plant BJ, Maher MM, MacSharry J, Murphy DM.

Chest. 2017 Jun;151(6):1272-1278. doi: 10.1016/j.chest.2017.03.005. Epub 2017 Mar 11.

PMID:
28300572
29.

A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis.

Dasgupta A, Kjarsgaard M, Capaldi D, Radford K, Aleman F, Boylan C, Altman LC, Wight TN, Parraga G, O'Byrne PM, Nair P.

Eur Respir J. 2017 Mar 15;49(3). pii: 1602486. doi: 10.1183/13993003.02486-2016. Print 2017 Mar. No abstract available.

30.

Toll-like receptor-induced expression of epithelial cytokine receptors on haemopoietic progenitors is altered in allergic asthma.

Tworek D, Heroux D, O'Byrne SN, Mitchell P, O'Byrne PM, Denburg JA.

Clin Exp Allergy. 2017 Jul;47(7):900-908. doi: 10.1111/cea.12913. Epub 2017 Mar 31.

PMID:
28252235
31.

The interaction between bronchoconstriction and cough in asthma.

Satia I, Badri H, Woodhead M, O'Byrne PM, Fowler SJ, Smith JA.

Thorax. 2017 Dec;72(12):1144-1146. doi: 10.1136/thoraxjnl-2016-209625. Epub 2017 Feb 24.

PMID:
28235887
32.

Methacholine challenge tests to demonstrate therapeutic equivalence of terbutaline sulfate via different Turbuhaler® devices in patients with mild to moderate asthma: Appraisal of a four-way crossover design.

Bjermer L, Gauvreau GM, Postma DS, O'Byrne PM, van den Berge M, Boulet LP, Beckman O, Persson T, Román J, Carlholm M, Schützer KM, Eckerwall G.

Pulm Pharmacol Ther. 2017 Jun;44:1-6. doi: 10.1016/j.pupt.2017.02.004. Epub 2017 Feb 20.

PMID:
28232118
33.

Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance.

Nair P, Martin JG, Cockcroft DC, Dolovich M, Lemiere C, Boulet LP, O'Byrne PM.

J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):649-659.e2. doi: 10.1016/j.jaip.2016.11.030. Epub 2017 Feb 2. Review.

PMID:
28163029
34.

The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given 'as needed' in mild asthma: study protocols for two randomised controlled trials.

O'Byrne PM, FitzGerald JM, Zhong N, Bateman E, Barnes PJ, Keen C, Almqvist G, Pemberton K, Jorup C, Ivanov S, Reddel HK.

Trials. 2017 Jan 10;18(1):12. doi: 10.1186/s13063-016-1731-4.

35.

Therapeutic interventions in severe asthma.

Canonica GW, Senna G, Mitchell PD, O'Byrne PM, Passalacqua G, Varricchi G.

World Allergy Organ J. 2016 Nov 28;9(1):40. eCollection 2016. Review.

36.

Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation.

Mitchell PD, Salter BM, Oliveria JP, El-Gammal A, Tworek D, Smith SG, Sehmi R, Gauvreau GM, Butler M, O'Byrne PM.

Clin Exp Allergy. 2017 Mar;47(3):331-338. doi: 10.1111/cea.12860. Epub 2017 Jan 28.

PMID:
27928844
37.

Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study.

Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, Lythgoe D, O'Byrne PM.

Lancet. 2017 Jan 14;389(10065):157-166. doi: 10.1016/S0140-6736(16)31399-X. Epub 2016 Nov 30.

PMID:
27912982
38.

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma.

O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW.

Respir Res. 2016 Nov 24;17(1):157.

39.

Anti-IgE and Biologic Approaches for the Treatment of Asthma.

Mitchell PD, El-Gammal AI, O'Byrne PM.

Handb Exp Pharmacol. 2017;237:131-152. doi: 10.1007/164_2016_65. Review.

PMID:
27864676
40.

Epithelial-Derived Cytokines in Asthma.

Mitchell PD, O'Byrne PM.

Chest. 2017 Jun;151(6):1338-1344. doi: 10.1016/j.chest.2016.10.042. Epub 2016 Nov 3. Review.

PMID:
27818325
41.

Rebuttal From Dr O'Byrne.

O'Byrne PM.

Chest. 2017 Jan;151(1):20-21. doi: 10.1016/j.chest.2016.09.024. Epub 2016 Oct 13. No abstract available.

PMID:
27746206
42.

POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management? Yes.

O'Byrne PM.

Chest. 2017 Jan;151(1):14-17. doi: 10.1016/j.chest.2016.09.021. Epub 2016 Oct 13. No abstract available.

PMID:
27746203
43.

Revisiting early intervention in adult asthma.

Haahtela T, Selroos O, O'Byrne PM.

ERJ Open Res. 2015 Sep 14;1(1). pii: 00022-2015. eCollection 2015 May. Review.

44.

Allergen-Induced Increases in Interleukin-25 and Interleukin-25 Receptor Expression in Mature Eosinophils from Atopic Asthmatics.

Tang W, Smith SG, Salter B, Oliveria JP, Mitchell P, Nusca GM, Howie K, Gauvreau GM, O'Byrne PM, Sehmi R.

Int Arch Allergy Immunol. 2016;170(4):234-242. Epub 2016 Sep 30.

45.

The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.

Todd CM, Salter BM, Murphy DM, Watson RM, Howie KJ, Milot J, Sadeh J, Boulet LP, O'Byrne PM, Gauvreau GM.

Pulm Pharmacol Ther. 2016 Dec;41:34-39. doi: 10.1016/j.pupt.2016.09.005. Epub 2016 Sep 14.

PMID:
27640067
46.

Measuring Eosinophils to Make Treatment Decisions in Asthma.

Nair P, O'Byrne PM.

Chest. 2016 Sep;150(3):485-7. doi: 10.1016/j.chest.2016.07.009. No abstract available.

PMID:
27613975
47.

Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.

O'Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M, Larsson B, Cullberg M, Nair P.

Lancet Respir Med. 2016 Oct;4(10):797-806. doi: 10.1016/S2213-2600(16)30227-2. Epub 2016 Aug 27.

PMID:
27574788
48.

A dual CysLT1/2 antagonist attenuates allergen-induced airway responses in subjects with mild allergic asthma.

Gauvreau GM, Boulet LP, FitzGerald JM, Cockcroft DW, Davis BE, Leigh R, Tanaka M, Fourre JA, Tanaka M, Nabata T, O'Byrne PM.

Allergy. 2016 Dec;71(12):1721-1727. doi: 10.1111/all.12987. Epub 2016 Aug 9.

PMID:
27444660
49.

Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction.

Satia I, Tsamandouras N, Holt K, Badri H, Woodhead M, Ogungbenro K, Felton TW, O'Byrne PM, Fowler SJ, Smith JA.

J Allergy Clin Immunol. 2017 Mar;139(3):771-779.e10. doi: 10.1016/j.jaci.2016.04.045. Epub 2016 Jun 15.

50.

Biologics and the lung: TSLP and other epithelial cell-derived cytokines in asthma.

Mitchell PD, O'Byrne PM.

Pharmacol Ther. 2017 Jan;169:104-112. doi: 10.1016/j.pharmthera.2016.06.009. Epub 2016 Jun 27. Review.

PMID:
27365223

Supplemental Content

Loading ...
Support Center